Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Expands Dolutegravir Approval to Infants With HIV-1 Weighing at Least 2 kg

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at patientcareonline.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The FDA has expanded the approval of the HIV drug Dolutegravir to include infants with HIV-1 who weigh at least 2 kg, allowing earlier access to this treatment for a vulnerable patient group.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 26 Aug 2026 and 3 Sep 2026.

◆ ◆ The Wire takeaway

HIV treatment providers can now offer dolutegravir to infants earlier, broadening your treatment reach. This approval opens new early-stage paediatric HIV care opportunities that you must act on quickly.

◆ Coverage

4 sources · first reported 26 Aug 2026 · latest 3 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDAdolutegravirHIVinfantsdrug-approval